Image pharmaphorum Editor Digital What HCPs think about medical tweetorials Twitter has been used by health professionals for over a decade to share medical knowledge and education. Views & Analysis COVID-19 has propelled the regulatory industry years ahead Janssen’s Saskia De Haes, VP EMEA Regulatory Affairs, looks at how the pandemic response has shaped tomorrow’s regulatory landscape. News Positive safety data for long-term use of MS drug Kesimpta Multiple sclerosis drug Kesimpta has shown promising safety data for patients who are exposed to it for extended periods. Sales & Marketing Launch excellence: escaping the complexity trap IQVIA’s Sarah Rickwood and Markus Gores look at how to deliver consistent launch performance in an increasingly complex world. Load more results
Digital What HCPs think about medical tweetorials Twitter has been used by health professionals for over a decade to share medical knowledge and education.
Views & Analysis COVID-19 has propelled the regulatory industry years ahead Janssen’s Saskia De Haes, VP EMEA Regulatory Affairs, looks at how the pandemic response has shaped tomorrow’s regulatory landscape.
News Positive safety data for long-term use of MS drug Kesimpta Multiple sclerosis drug Kesimpta has shown promising safety data for patients who are exposed to it for extended periods.
Sales & Marketing Launch excellence: escaping the complexity trap IQVIA’s Sarah Rickwood and Markus Gores look at how to deliver consistent launch performance in an increasingly complex world.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.